Walk on water might be soon an action easy to do for anyone. The new liquid created by the Moratex Institute of Security Technologies in Poland becomes solid in an instant when shaken or hit. Its main use will be filling the anti-bullet vests. The liquid retains bullets better and diminishes the deflection, which minimizes the risks that a bullet can still go through the clothing. It also diminishes the bend in the fabric of the west when retaining the bullet. The ordinary vests bend and might give painful sensations even when the bullet has not reached the body. The scientists say that it is useful in other areas besides the anti-ballistic one. Soon, the liquid will be available for purchase.
The University of Delaware had worked on similar projects from 2000. Folks at Anastasia Date (youtube.com) have heard that the laboratory workers called the substance Liquid Armor. They prepared a substance that would improve the doctor’s attire. The latex gloves often get broken or pierced, exposing the doctors to infections. The Liquid Armor is more resistant and would protect the doctors from cuts and needle sticks. The spacesuit manufacturers announced their interest towards the material as well.
A recent boom in the biotech industry saw venture capital investment climbing from $4.52 billion in 2013 to $5.29 billion in 2014. Joel Marcus, who has been in the industry for 30 years and is currently chief executive of Alexandria Real Estate Equities Inc., recently discussed trends contributing to the growing success. Marcus believes the industry has changed. Science is constantly evolving as new discoveries are continuously being made. Many fields have seen dramatic progress over the years and with the emergence of new science, a new generation of companies has emerged beyond the traditional Genentech and Amgen. There are exciting areas of opportunities developing.
For example, the neuroscience field which hasn’t seen as much progress in clinical trials as cancer research, is poised to excel in the current boom. Lack of funding for the FDA and NIH may hinder progress, though, as funding issues are causing young scientists to leave the public sector. The occupancy of properties is also a problem. There is fierce competition for space in the current biotech hubs of San Francisco and Cambridge, especially Cambridge where occupancy is already at 97%. Pharmaceutical, tech, and other companies, like Uber, all want space in these areas as well. However, with the resurgence of the biotech industry, other hubs are likely to emerge. NYC is a strong hub already and Texas is prepped to explode. With quality research and clinical practice, the only thing Texas lacks to become the next big hub is a strong commercial sector.
But why are biotech start-ups succeeding in an industry that doesn’t usually breed success? If you remember a piece I wrote back in January on Mark Ahn, the entrepreneur, executive, and consultant says resilience is the key. It takes longer for a product to reach the market in the biotech industry because of long development cycles and strict regulations. Therefore, companies generally require several rounds of outside funding before a product generates income. According to Mark Ahn, it doesn’t help to get caught up in what’s trending or get involved in the newest hype. Instead companies that succeed generally stick to their business plan.
A report on Reddit states a new streaming service called Sling will be released tomorrow. This service will be an online only option for Dish Network customers, and the primary draw to the service is the ESPN package. The cost will be $20 and will spare the client from having to pay for additional channels.
Sling will also carry ESPN2 the Turner channels. For an extra $5 you can purchase the children’s package that includes Disney Baby TV, Boomerang, Disney Junior, Disney XD and Duck TV. The “News & Info Extra”, which is also $5 throws in Bloomberg TV, Cooking Channel, DIY and CNN’s HLN.
As far as Sergio Andrade Gutierrez knows, there has not been a direct statement on the resolution that Sling is supposed to deliver, but it is reported to be as crisp as Hulu or Netflix.
Sling is currently available by invitation only. It can be signed up for here.
In PR Newswire’s article “Mark Ahn Explains Why Some Biotech Startups Succeed, While Others Wither” we get a few tips on what differentiates a successful and unsuccessful biotech start up, and how to profit from investing in this industry. Mark Ahn has more than 20 years of professional experience in the biopharmaceutical industry.
According to Ahn, successful biotech startups have several rounds of funding from outside investors. This is necessary due to the long development cycles of a drug. Multiple rounds of funding is needed to ensure the development meets the regulation standards of the industry. The biotech startup cannot generate any revenue until after the product is approved for market sale, so its success depends on its investors.
In light of this, Ahn recommends investors acquire stakes in multiple startups rather than investing in one single biotech company. The startup’s resilience and successes will be proven over time. Investing in multiple companies and avoiding trends reduces the risk that your investment will go to waste. In other words, don’t put all your eggs in one basket.
Have you heard of Mark Ahn? If you have not, then please stay tuned. In biotech Mark Ahn seems to be everywhere and we are not quite sure how he has the time! NOt only is he wearing many hats in the biosciences industry; but he is also running companies and educating the next wave of change makers as an adjunct professor and contributor to many literary publications in his field.
Currently Dr. Ahn is residing in Portland, Oregon and is currently running a successful biotech consulting firm, Pukana Partners. This is not Dr. Ahn’s first go around in the entrepreneur seat though, previously he served as founder and CEO of Hana Biosciences. He also served as CEO of Galena Biopharma. It seems as though he is balancing a successful business while still maintaining hunger for advancement in his field.
A regular contributor to peer review journals and author of “Building the Case for Biotechnology: Management Case Studies in Science, Laws, Regulations, Politics, and Business”, amongst other works. He also finds himself guiding the next area of biotech consults, and future entrepreneurs as an adjunct professor at PSU. There is something to be said about the successful CEO who still finds time to educate and mentor in their field. Sharing the expertise and experience that Dr. Mark Ahn has of the biotech business is priceless.
Biotech companies large and small are also taking Dr. Ahn into account. His consulting of start up businesses can really change the effectiveness and efficiency so that companies can concentrate on their development. Growth and development in biotech ultimately benefits us as when it is done effectively and that is what Dr. Mark Ahn has set out to do.
Although we can not really pinpoint where you might find Dr. Ahn in the future, his ever evolving career and business endeavors have taken him across the globe many times; we are sure that you will be able to track him down with his head in a book and his feet on the pavement. Always learning, creating, evolving, and sharing his love for the advancement of business and biotechnology.